SecBot SecBot
6-K ·Filed Jun 15, 2026

ASND

Ascendis Pharma A/S
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001193125-26-270227
Notable filing: 6-K
Actionable Insight ▲ Bullish

The long-term efficacy and safety data significantly derisk TransCon PTH and support its commercial potential in hypoparathyroidism. Monitor upcoming quarterly reports for revenue growth from Yorvipath (palopegteriparatide) sales, as this data should aid physician adoption.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$223.29
T+0 close · Jun 15, 2026 · via day close
Latest settled
+16.80%
T+60 · $260.81
Vs SPY
+15.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $223.29entry
  2. T+1 · 5mo ago +3.54%α +4.14% · $231.20
  3. T+5 · 5mo ago +2.11%α +3.49% · $228.00
  4. T+20 · 4mo ago +18.78%α +19.53% · $265.22
  5. T+60 · 2mo ago +16.80%α +15.80% · $260.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma reported Week 182 data from the Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in hypoparathyroidism, showing sustained efficacy and safety over 3.5 years. Key results include 86% responders, 100% independence from active vitamin D, 96% independence from therapeutic calcium, normalized kidney function, and no anti-PTH antibodies. The data reinforce the drug's long-term value proposition.

Key Facts

  • 86% of patients met the multi-component responder endpoint (normal serum calcium, no active vitamin D, ≤600 mg/day calcium).
  • 100% of patients achieved independence from active vitamin D.
  • 96% of patients achieved independence from therapeutic doses of calcium (<600 mg/day).
  • Mean eGFR increased by 11.0 mL/min/1.73m² from baseline and was maintained through Week 182, contrasting with age-related decline.
  • Mean 24-hour urine calcium normalized within 26 weeks and remained normal.
  • No patients developed anti-PTH antibodies during 3.5 years of treatment.
  • No new safety signals; no discontinuations related to study drug.

Financial Impact

No financial data provided; the filing contains clinical trial results only.

Risk Factors

  • Commercial adoption may be slower than expected due to competition or payer dynamics.
  • Regulatory updates or label changes could impact market access.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-270227
Document: 0001193125-26-270227-index-headers.html0001193125-26-270227
Document: 0001193125-26-270227-index.html0001193125-26-270227
Document: 0001193125-26-270227.txt0001193125-26-270227

Track record

41 reports on ASND

Performance horizon

13 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  5. Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
  8. Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Wed (10h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026